Orphalan has launched a global Phase 3 study that could reshape first-line copper-chelation therapy in Wilson disease by testing an investigational once-daily formulation of trientine tetrahydrochloride directly against D-penicillamine. The TRADITiONAL trial will enroll newly diagnosed children and adults and randomize participants to receive either the once-daily trientine formulation or D-penicillamine for 48 weeks. The study is specifically designed around first-line treatment rather than switching patients who have already demonstrated intolerance to another chelator, making it a more ambitious development step for a drug class traditionally positioned after D-penicillamine in some treatment pathways.
The practical issue behind the program is adherence. Wilson disease requires lifelong treatment because patients have an inherited defect in copper handling that causes copper to accumulate in the liver, brain and other organs. Chelating medicines bind copper so it can be eliminated, but treatment schedules can be burdensome and often require careful separation from meals. Orphalan is testing whether simplifying trientine to one daily dose can maintain effective copper control while making a lifelong regimen easier to follow.
What causes Wilson disease and why does treatment have to continue for life?
Wilson disease is caused by pathogenic variants in the ATP7B gene, which disrupt normal transport of copper out of liver cells and into bile.
Because the body cannot eliminate copper normally, the metal gradually accumulates. The liver often bears the earliest burden, but copper can also deposit in the brain, eyes and other tissues.
Patients can present with hepatitis, cirrhosis, liver failure, movement disorders, psychiatric symptoms or combinations of hepatic and neurological disease.
The key point is that treatment does not repair the ATP7B mutation. Chelators remove excess copper and prevent additional accumulation while therapy continues.
Stopping effective treatment allows copper to build up again, which is why adherence is not merely desirable. It is central to long-term disease control.
This makes Wilson disease particularly suitable for a trial asking whether dosing simplicity matters.
Why is D-penicillamine still such an important comparator?
D-penicillamine is one of the oldest and most established copper-chelating therapies for Wilson disease.
It can be effective at promoting copper excretion, but treatment can be complicated by adverse effects and administration requirements. Some patients develop hypersensitivity reactions, blood abnormalities, renal problems or neurological worsening, particularly during early treatment.
Because of its long clinical history, however, D-penicillamine remains a relevant first-line comparator.
A new formulation seeking to become a primary treatment option must demonstrate not simply that it removes copper but that its overall balance of efficacy, tolerability and practicality is competitive with a medicine clinicians already know well.
TRADITiONAL is therefore more informative than a single-arm trientine study because both groups will be treated prospectively within the same protocol.
What is different about Orphalan’s once-daily trientine formulation?
Trientine is not a new molecular concept. The novelty lies in formulation and dosing strategy.
The investigational product uses trientine tetrahydrochloride, or TETA 4HCl, administered once daily.
Existing trientine products and traditional chelation regimens may require multiple daily doses, often separated from food because dietary intake can affect absorption.
A once-daily treatment could reduce the number of opportunities for missed doses and make medication timing easier for patients attending school, work or traveling.
That convenience is clinically relevant only if copper control remains adequate throughout the dosing interval.
The Phase 3 trial therefore needs to show that simplifying the schedule does not sacrifice efficacy.
Who can enter the TRADITiONAL study?
The study includes adults and children aged eight years and older who weigh at least 25 kilograms and have a recent Wilson disease diagnosis.
Participants must generally be treatment naïve to copper chelation, although some limited prior zinc use can be allowed under the protocol.
This design helps answer the first-line question directly. If most participants had already failed D-penicillamine, the trial would be testing rescue therapy rather than whether once-daily trientine can serve as an initial treatment.
Participants are randomly allocated to the trientine formulation or D-penicillamine and undergo 48 weeks of treatment, with multiple clinical visits, blood testing, urine testing and patient-reported assessments.
The inclusion of children is significant because Wilson disease can be diagnosed in childhood and may require decades of treatment.
A formulation that simplifies adherence could therefore have particularly large lifetime implications for younger patients.
What endpoints will actually show whether the new regimen works?
Copper control is the central biological outcome.
Wilson disease trials can assess measures including serum copper, urinary copper excretion, non-ceruloplasmin-bound copper and other laboratory indicators intended to show whether excess copper is being removed or controlled.
Clinical assessments of liver function, neurological status and adverse events are also important.
Because the study lasts 48 weeks, it is long enough to evaluate more than short-term pharmacokinetics but too short to demonstrate lifetime prevention of cirrhosis or neurological deterioration.
Patient-reported treatment satisfaction and well-being are being collected at selected visits, according to the trial description.
Those measures matter because the entire strategic rationale of once-daily treatment partly depends on reducing burden.
A formulation that produces equivalent copper control but is substantially easier to take could still deliver meaningful clinical value even without being biologically more potent.
Why is adherence so difficult with copper chelation?
Many chronic medicines can be taken with breakfast and forgotten until the next day. Traditional Wilson disease therapy can be more complicated.
Chelators may need to be taken on an empty stomach and separated from food, other medicines or supplements. Multiple daily dosing creates repeated scheduling decisions.
For a newly diagnosed teenager, maintaining those rules through school, social activities and travel can be challenging.
Adults can face similar problems around work and family routines.
Poor adherence may not produce immediate symptoms, which can make the danger less visible. Copper can accumulate gradually, and clinical deterioration may appear only after the patient has already spent substantial time undertreated.
Simplifying dosing therefore addresses a genuine disease-management problem rather than merely a marketing convenience.
Could once-daily trientine reduce toxicity compared with D-penicillamine?
That is one of the important questions the Phase 3 study can explore.
Trientine is commonly used as an alternative chelator and is generally viewed as having a different tolerability profile from D-penicillamine.
However, it is not free of adverse effects, and changing the dosing formulation can alter drug exposure.
TRADITiONAL will therefore need to compare treatment discontinuations, laboratory abnormalities, neurological worsening and other adverse events prospectively.
If once-daily trientine produces similar copper control with fewer clinically important side effects, the regimen could become attractive even before convenience is considered.
If efficacy is weaker, however, easier dosing may not be enough to justify first-line substitution.
Why is first-line positioning commercially more important than second-line use?
A drug used only after intolerance or failure of another medicine addresses a narrower population.
First-line approval puts the therapy in consideration at the moment of diagnosis, before physicians and patients have committed to another long-term chelator.
That creates a larger commercial opportunity and can shape treatment guidelines more fundamentally.
Orphalan already has experience commercializing trientine therapy in Wilson disease. The new once-daily formulation is therefore an attempt to expand beyond having a product within the category toward changing how initial treatment is delivered.
A head-to-head Phase 3 trial against D-penicillamine provides the kind of evidence required for that ambition.
What are the risks of making treatment easier if patients misunderstand “once daily” as lower intensity?
Simplification can improve adherence, but it can also create a perception that the disease is less serious.
Wilson disease remains a lifelong genetic disorder regardless of how easy the medication becomes to take.
Patients still require routine monitoring of copper status, liver function, neurological symptoms and treatment safety.
Dose adjustment may be needed according to clinical response.
The goal of a once-daily formulation is to reduce logistical burden, not reduce the need for specialist follow-up.
Clear patient education will therefore remain essential if the product eventually reaches market.
How could the study affect pediatric Wilson disease care?
Children diagnosed before severe organ damage develops may benefit enormously from reliable lifelong copper control.
The challenge is maintaining that treatment through adolescence and into adulthood.
A medication taken once each day could fit more naturally into family routines and later independent self-management than a complex multi-dose schedule.
Pediatric tolerability will also matter because children may remain on therapy much longer than adult patients starting at middle age.
The Phase 3 study’s lower age limit of eight years gives Orphalan an opportunity to build a substantial evidence base in younger patients rather than extrapolating entirely from adults.
Does launching Phase 3 mean once-daily trientine is already proven effective?
No.
The investigational formulation is entering the study precisely because the comparative question is unresolved.
Trientine itself is an established copper chelator, but formulation, exposure and dosing interval still need to be validated.
A once-daily version cannot simply rely on the reputation of other trientine products if its pharmacokinetics or clinical performance differ.
Randomization against D-penicillamine will provide a much stronger basis for comparing efficacy and safety than uncontrolled experience.
Regulatory authorities will ultimately determine whether the complete data support first-line labeling.
What should patients and hepatologists watch over the next 48 weeks?
The most important issue is whether once-daily trientine achieves stable copper control across the entire dosing interval.
Investigators will also watch for early neurological worsening, a known concern when initiating copper chelation in some symptomatic patients.
Treatment discontinuation rates could reveal whether one regimen is meaningfully easier to tolerate.
Patient-reported satisfaction may provide a direct measure of the convenience advantage.
Finally, subgroup data will matter. Newly diagnosed hepatic patients may respond differently from those presenting with neurological disease, while pediatric patients may have different exposure and adherence patterns from adults.
TRADITiONAL is therefore not simply a formulation study. It is asking whether the daily life of Wilson disease treatment can be simplified without weakening the biological control that prevents copper from causing irreversible organ damage.
If the answer is yes, a relatively straightforward dosing change could become clinically more important than its chemistry suggests.
